Suppr超能文献

囊性纤维化中的特异性促解决脂质介质。

Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis.

机构信息

INSERM, U1151, Institut Necker Enfants Malades, 75993 Paris, France.

出版信息

Int J Mol Sci. 2018 Sep 21;19(10):2865. doi: 10.3390/ijms19102865.

Abstract

In cystic fibrosis (CF), impaired airway surface hydration (ASL) and mucociliary clearance that promote chronic bacterial colonization, persistent inflammation, and progressive structural damage to the airway wall architecture are typically explained by ion transport abnormalities related to the mutation of the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. However, the progressive and unrelenting inflammation of the CF airway begins early in life, becomes persistent, and is excessive relative to the bacterial burden. Intrinsic abnormalities of the inflammatory response in cystic fibrosis have been suggested but the mechanisms involved remain poorly understood. This review aims to give an overview of the recent advances in the understanding of the defective resolution of inflammation in CF including the abnormal production of specialized pro-resolving lipid mediators (lipoxin and resolvin) and their impact on the pathogenesis of the CF airway disease.

摘要

在囊性纤维化 (CF) 中,气道表面水合作用 (ASL) 受损和黏液纤毛清除功能障碍导致慢性细菌定植、持续炎症和气道壁结构的进行性结构损伤,通常可以用与编码囊性纤维化跨膜电导调节因子 (CFTR) 通道的基因突变相关的离子转运异常来解释。然而,CF 气道的进行性和持续不断的炎症早在生命早期就开始了,持续存在且相对于细菌负担而言过度。已经提出了 CF 中炎症反应的内在异常,但相关机制仍知之甚少。本综述旨在概述对 CF 中炎症消退缺陷的理解的最新进展,包括专门的促解决脂质介质(脂氧素和 resolvin)的异常产生及其对 CF 气道疾病发病机制的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7dc6/6213393/67b65345db5d/ijms-19-02865-g001.jpg

相似文献

1
Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis.
Int J Mol Sci. 2018 Sep 21;19(10):2865. doi: 10.3390/ijms19102865.
2
Pro-resolving lipid mediator Resolvin D1 serves as a marker of lung disease in cystic fibrosis.
PLoS One. 2017 Feb 3;12(2):e0171249. doi: 10.1371/journal.pone.0171249. eCollection 2017.
3
Cystic fibrosis and lipoxins.
Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):263-70. doi: 10.1016/j.plefa.2005.05.015.
4
The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease.
Front Pharmacol. 2020 Sep 2;11:1290. doi: 10.3389/fphar.2020.01290. eCollection 2020.
6
Modulation of Ion Transport to Restore Airway Hydration in Cystic Fibrosis.
Genes (Basel). 2021 Mar 22;12(3):453. doi: 10.3390/genes12030453.
7
[Physiopathology of cystic fibrosis lung disease].
Rev Mal Respir. 1999 Jun;16(3):339-45.
8
Airway surface liquid homeostasis in cystic fibrosis: pathophysiology and therapeutic targets.
Thorax. 2016 Mar;71(3):284-7. doi: 10.1136/thoraxjnl-2015-207588. Epub 2015 Dec 30.
9
Cystic Fibrosis: Pathophysiology of Lung Disease.
Semin Respir Crit Care Med. 2019 Dec;40(6):715-726. doi: 10.1055/s-0039-1694021. Epub 2019 Oct 28.
10
[CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
Arch Pediatr. 2003 Sep;10 Suppl 2:325s-332s. doi: 10.1016/s0929-693x(03)90047-9.

引用本文的文献

2
Fatty acid abnormalities in cystic fibrosis-the missing link for a cure?
iScience. 2024 Oct 11;27(11):111153. doi: 10.1016/j.isci.2024.111153. eCollection 2024 Nov 15.
3
Proresolving Lipid Mediators in the Respiratory System.
Annu Rev Physiol. 2025 Feb;87(1):491-512. doi: 10.1146/annurev-physiol-020924-033209. Epub 2025 Feb 3.
5
Mucosal Immunity in Cystic Fibrosis.
J Immunol. 2021 Dec 15;207(12):2901-2912. doi: 10.4049/jimmunol.2100424.
7
Nutrition in Cystic Fibrosis-Some Notes on the Fat Recommendations.
Nutrients. 2022 Feb 18;14(4):853. doi: 10.3390/nu14040853.
8
MicroRNAs in shaping the resolution phase of inflammation.
Semin Cell Dev Biol. 2022 Apr;124:48-62. doi: 10.1016/j.semcdb.2021.03.019. Epub 2021 Apr 29.
9
Specialized proresolving mediators in infection and lung injury.
Biofactors. 2021 Jan;47(1):6-18. doi: 10.1002/biof.1691. Epub 2020 Nov 28.
10
The Role of Specialized Pro-Resolving Mediators in Cystic Fibrosis Airways Disease.
Front Pharmacol. 2020 Sep 2;11:1290. doi: 10.3389/fphar.2020.01290. eCollection 2020.

本文引用的文献

1
Inflammation in cystic fibrosis: An update.
Pediatr Pulmonol. 2018 Nov;53(S3):S30-S50. doi: 10.1002/ppul.24129. Epub 2018 Jul 12.
3
Low linoleic and high docosahexaenoic acids in a severe phenotype of transgenic cystic fibrosis mice.
Exp Biol Med (Maywood). 2018 Mar;243(5):496-503. doi: 10.1177/1535370218758605.
4
Neutrophil extracellular traps and the dysfunctional innate immune response of cystic fibrosis lung disease: a review.
J Inflamm (Lond). 2017 Dec 28;14:29. doi: 10.1186/s12950-017-0176-1. eCollection 2017.
5
Resolvin D1 regulates epithelial ion transport and inflammation in cystic fibrosis airways.
J Cyst Fibros. 2018 Sep;17(5):607-615. doi: 10.1016/j.jcf.2017.11.017. Epub 2017 Dec 8.
6
Bypassing CFTR dysfunction in cystic fibrosis with alternative pathways for anion transport.
Curr Opin Pharmacol. 2017 Jun;34:91-97. doi: 10.1016/j.coph.2017.10.002. Epub 2017 Oct 21.
7
Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection.
Mucosal Immunol. 2018 Jan;11(1):35-49. doi: 10.1038/mi.2017.36. Epub 2017 Apr 19.
8
The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.
Am J Physiol Lung Cell Mol Physiol. 2017 Jun 1;312(6):L912-L925. doi: 10.1152/ajplung.00178.2016. Epub 2017 Mar 30.
9
Structural elucidation and physiologic functions of specialized pro-resolving mediators and their receptors.
Mol Aspects Med. 2017 Dec;58:114-129. doi: 10.1016/j.mam.2017.03.005. Epub 2017 Mar 31.
10
Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.
Hum Mol Genet. 2016 Oct 15;25(20):4590-4600. doi: 10.1093/hmg/ddw290.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验